
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
over 27 years ago
Health Status and Satisfaction with Pharmacy Servicesover 27 years ago
A New Physician's Guide to Evaluation Managed Care Opportunitiesover 27 years ago
Technology Assessment and the Drug Use Process





